BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mueller JK, Riederer P, Müller WE. Neuropsychiatric Drugs Against COVID-19: What is the Clinical Evidence? Pharmacopsychiatry 2022;55:7-15. [DOI: 10.1055/a-1717-2381] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Lu LC, Chao CM, Chang SP, Lan SH, Lai CC. Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis. J Infect Public Health 2022;15:1259-64. [PMID: 36272390 DOI: 10.1016/j.jiph.2022.10.010] [Reference Citation Analysis]
2 Gumusoglu SB, Schickling BM, Vignato JA, Santillan DA, Santillan MK. Selective serotonin reuptake inhibitors and preeclampsia: a quality assessment and meta-analysis. Pregnancy Hypertension 2022. [DOI: 10.1016/j.preghy.2022.08.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Karwaciak I, Karaś K, Sałkowska A, Pastwińska J, Ratajewski M. Chlorpromazine, a Clinically Approved Drug, Inhibits SARS-CoV-2 Nucleocapsid-Mediated Induction of IL-6 in Human Monocytes. Molecules 2022;27:3651. [PMID: 35744777 DOI: 10.3390/molecules27123651] [Reference Citation Analysis]
4 Bauer M, Juckel G. Covid-19: Contributions from Psychopharmacology. Pharmacopsychiatry 2022;55:5-6. [DOI: 10.1055/a-1720-8855] [Reference Citation Analysis]